<DOC>
	<DOCNO>NCT02863718</DOCNO>
	<brief_summary>This prospective , multicenter , randomize , placebo-controlled , double-blind phase III study compare efficacy safety oral ibrutinib previously untreated Binet stage A CLL patient without treatment indication accord iwCLL guideline risk early disease progression . For event-free survival ( EFS ) , improvement 24 month untreated intermediate ( ) high risk CLL 48 month subject treat ibrutinib consider clinically relevant . Ibrutinib / placebo administer continuously orally symptomatic disease progression , unacceptable toxicity , voluntary treatment withdrawal , whichever occur first .</brief_summary>
	<brief_title>Ibrutinib Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk Disease Progression</brief_title>
	<detailed_description>The primary objective study demonstrate superiority ibrutinib placebo prolong EFS subject treatment-naïve CLL stage A intermediate ( ) high risk disease progression . All subject intermediate , ( ) high risk randomize experimental treatment arm treat active progressive disease treatment indication accord iwCLL-Guidelines objective demonstrate prolongation EFS ibrutinib arm . EFS define time randomization active progressive disease treatment indication accord iwCLL-Guidelines subsequent treatment CLL death . The secondary objective : - To evaluate prolongation overall survival ibrutinib versus placebo - To evaluate safety ibrutinib versus placebo</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<criteria>Previously untreated CLL Stage Binet A without need treatment Age ≥ 18 year Life expectancy ≥ 6 month ECOG 0 2 Signed write informed consent Patient experimental arm willing use highly effective contraceptive method Male subject experimental treatment arm ( placebo / ibrutinib ) must : Agree donate semen study drug therapy period end study drug therapy . For male restriction apply 3 month last dose study medication . Agree share study medication another person . Be counseled pregnancy precaution risk fetal exposure . Willingness inform general practitioner Any prior CLL specific therapy Prior treatment Ibrutinib BTK inhibitor Chronic use steroid excess prednisone 20mg/day equivalent Active infection require systemic antibiotic An lifethreatening illness , medical condition , organ system dysfunction , investigator 's opinion could compromise subject 's safety , interfere absorption metabolism Ibrutinib capsule , put study outcome undue risk Pregnant lactating female Central nervous system ( CNS ) involvement document spinal fluid cytology image . Subjects sign symptom suggestive leukemic meningitis history leukemic meningitis must lumbar puncture procedure perform within two week prior randomization Known second malignancy limit survival less two year Known Human Immunodeficiency Virus ( HIV ) , active Hepatitis B Virus ( HBV ) and/or active Hepatitis C Virus ( HCV ) infection . Any following laboratory abnormality : 1 . Serum aspartate aminotransferase ( AST ) /serum glutamicoxaloacetic transaminase ( SGOT ) alanine transaminase ( ALT ) /serum glutamate pyruvate transaminase ( SGPT ) &gt; 2.5 x upper limit normal ( ULN ) 2 . Serum total bilirubin &gt; 1.5 ULN ( exception Gilbert 's Syndrome ) 3 . Creatinine clearance &lt; 30ml/min Requires anticoagulant warfarin phenoprocoumon Requires anticoagulant oral direct Xa Inhibitors ( rivaroxaban , apixaban , edoxaban ) History stroke intracranial hemorrhage within 6 month prior randomization Requires treatment strong CYP3A4/5 Inhibitors Participation clinical study CLL take investigational therapy would interfere study drug disease CLL within 28 day prior initiate treatment . Prisoners subject institutionalized regulatory court order person dependence sponsor investigator Patients uncontrolled autoimmune hemolytic anemia autoimmune thrombocytopenia For male restriction apply 3 month last dose study medication . Agree share study medication another person . Be counseled pregnancy precaution risk fetal exposure . Willingness inform general practitioner</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>CLL</keyword>
</DOC>